Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000950170-25-021346·AN2 Therapeutics, Inc.
Schedule 13G ownership disclosure
AN2 Therapeutics, Inc.
Common Stock, $0.00001 par value · CUSIP: 037326105
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- TCG Crossover GP I, LLC
Shares: 0 · Class: 0%
- TCG Crossover Fund I, L.P.
Shares: 0 · Class: 0%
- Chen Yu
Shares: 0 · Class: 0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-021346
- Form type
- SCHEDULE 13G/A
- Filer
- AN2 Therapeutics, Inc.
- CIK
- CIK 1880438
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership